Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Status:
Active, not recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase II study of an investigational drug, sunitinib malate in patients
with advanced malignant paraganglioma or phaeochromocytoma cancer. Paragangliomas (PGs) are
tumours that arise from the para-sympathetic system in the head and neck and sympathetic
system in the thorax and abdomen. Paragangliomas that secrete hormones (catecholamines) from
the adrenal glands are called pheochromocytomas (PCs). In this study, patients whose disease
has advanced or spread despite prior standard therapy, will receive sunitinib for 4-weeks
followed by a 2-week rest period, for up to 12 months, in the absence of disease progression.
Sunitinib is an investigational drug, which has been shown to shrink tumours in several
tumour models. The study will evaluate the efficacy as well as the toxicity profile of
sunitinib when used as an alternative treatment for patients with PG/PC tumours.